Certara, Inc. (CERT)

NASDAQ: CERT · IEX Real-Time Price · USD
14.64
+0.23 (1.60%)
Dec 1, 2023, 4:00 PM EST - Market closed
1.60%
Market Cap 2.34B
Revenue (ttm) 352.96M
Net Income (ttm) -33.73M
Shares Out 159.85M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE 30.82
Dividend n/a
Ex-Dividend Date n/a
Volume 547,738
Open 14.35
Previous Close 14.41
Day's Range 14.12 - 14.67
52-Week Range 11.81 - 24.96
Beta 1.51
Analysts Buy
Price Target 50.29 (+243.51%)
Earnings Date Nov 8, 2023

About CERT

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled se... [Read more]

Sector Healthcare
IPO Date Dec 11, 2020
Employees 1,204
Stock Exchange NASDAQ
Ticker Symbol CERT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CERT stock is "Buy." The 12-month stock price forecast is $50.29, which is an increase of 243.51% from the latest price.

Price Target
$50.29
(243.51% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.

12 days ago - GlobeNewsWire

Certara Reports Third Quarter 2023 Financial Results

PRINCETON, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023.

25 days ago - GlobeNewsWire

Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference

PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 a...

7 weeks ago - GlobeNewsWire

Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software

Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines

2 months ago - GlobeNewsWire

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor co...

3 months ago - GlobeNewsWire

Certara Simcyp™ Group Awarded Two New Grants from US FDA

Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations Programs focus on use of ...

3 months ago - GlobeNewsWire

Certara stock drops after biotech software company misses profit target

Certara Inc. CERT, -2.56% stock was down 14.6% in premarket trades on Thursday after the biotech software company missed Wall Street's adjusted earnings and revenue targets and said its 2023 profit wo...

4 months ago - Market Watch

Certara Reports Second Quarter 2023 Financial Results

PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023.

4 months ago - GlobeNewsWire

Certara & Xybion Partner to Integrate Nonclinical R&D Software to Streamline Assessing Drug Safety & Efficacy

PRINCETON, NJ / ACCESSWIRE / August 8, 2023 / Xybion Digital Inc. (TSXV:XYBN) ("Xybion"), a global, low-code SaaS company that enables digital transformation in highly regulated labs and Certara, Inc....

4 months ago - Accesswire

Certara collaborates with Korea Institute of Toxicology to ensure FDA submission-ready SEND dataset

SEOUL, South Korea--(BUSINESS WIRE)--Certara, Inc. (Nasdaq: CERT), a global leader in Biosimulation, today announced that a Korea Institute of Toxicology (KIT) have decided to implement Certara's Pinn...

4 months ago - Business Wire

Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023

PRINCETON, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023...

5 months ago - GlobeNewsWire

Certara to Participate in the Jefferies Global Healthcare Conference

PRINCETON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Heal...

6 months ago - GlobeNewsWire

Certara Reports First Quarter 2023 Financial Results

PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2023.

7 months ago - GlobeNewsWire

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year

Asserts Certara's leadership in advancing the development and approval of new drugs for patients Asserts Certara's leadership in advancing the development and approval of new drugs for patients

7 months ago - GlobeNewsWire

Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference

PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023...

8 months ago - GlobeNewsWire

Are These 3 Small Momentum Stocks Setting Up Big Gains?

MINISO Group Holding Limited (NYSE: MNSO), PDF Solutions Inc. (NASDAQ: PDFS), and Certara Inc. (NASDAQ: CERT) are relatively unknown stocks currently showing strong price momentum.

Other symbols: MNSOPDFSRBA
9 months ago - MarketBeat

A.I. Coming to Certara's D360 Scientific Informatics Software

New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses. New deep learning capabilities will provide data a...

9 months ago - GlobeNewsWire

Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types

Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies Simcyp Simulator has been utilized to inform more than 300 label clai...

9 months ago - GlobeNewsWire

Certara Reports Fourth Quarter and Full Year 2022 Financial Results

Annual Revenue Grows 17% on a Reported Basis and 20% at Constant Currency Annual Revenue Grows 17% on a Reported Basis and 20% at Constant Currency

9 months ago - GlobeNewsWire

Certara Announces Transition Plan for Chief Financial Officer

PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), announced today that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective April 1, 2023. ...

9 months ago - GlobeNewsWire

Certara to Participate in the Barclays Global Healthcare Conference

PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Barclays Global Healt...

9 months ago - GlobeNewsWire

Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023

PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and ful...

10 months ago - GlobeNewsWire

Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation

Certara improves software capabilities by expanding into deep learning and data fabric Certara improves software capabilities by expanding into deep learning and data fabric

11 months ago - GlobeNewsWire

Certara Announces the Completion of Arsenal Capital Partners' Investment and the Appointment of David Spaight to the Board of Directors

Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Priva...

1 year ago - GlobeNewsWire

Certara Reports Third Quarter 2022 Financial Results

Biosimulation software and services fuel third quarter growth Biosimulation software and services fuel third quarter growth

1 year ago - GlobeNewsWire